Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancerJessica D. Sun, Charles P. Hart, Ayesha S. Ruprell et al.|Cancer Biology & Therapy|2015Cited by 51
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.Jessica D. Sun, Charles P. Hart, Dharmendra Ahluwalia et al.|PubMed|2015Cited by 27
Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibitionFanying Meng, Charles P. Hart, Deepthi Bhupathi et al.|BMC Cancer|2015Cited by 24
14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer TreatmentMark Matteucci, Heli Huang, Charles P. Hart et al.|Journal of Medicinal Chemistry|2011Cited by 21